The recent ONC report on regulation of health IT, such as mobile medical apps, raises lots of questions but illustrates the hurdles to drafting practical guidance
Express Scripts warned of building an anti-Sovaldi coalition. If payers are unwilling to pay for such drugs, or band against their makers, where does pharma go from here?